



Karen N Price

Contact

Karen N Price

Publications (43)

Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GECAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. *J Clin Oncol* 2018; 36:1073-1079.

Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. *J Clin Oncol* 2017; 35:1179-1188.

Pruneri G, Regan M, Gelber R, Munzone E, Canello G, Price K, Kammler R, Goldhirsch A, Gianni L, Ruhstaller T, Láng I, Criscitiello C, Curigliano G, Viale G, Vingiani A, Gray K, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat* 2016; 158:323-31.

Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. *J Clin Oncol* 2016

Chirgwin J, Colleoni M, Láng I, Neven P, Forbes J, Rabaglio M, Smith I, Goldhirsch A, Gelber R, Debled M, Ejlertsen B, Price K, Coates A, Giobbie-Hurder A, Thürlimann B. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. *J Clin Oncol* 2016; 34:2452-9.

Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. *J Clin Oncol* 2016; 34:1601-10.

Colleoni M, Coates A, Gelber R, Castiglione M, Gianni L, Thürlimann B, Forbes J, Karlsson P, Price K, Sun Z, Goldhirsch A. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. *J Clin Oncol* 2016

Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. *Breast Cancer Res Treat* 2015; 154:543-55.

Regan M, Sessa F, Peg Cámara V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szóke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res Treat* 2015

Metzger Filho O, Coates A, Regan M, Price K, Debled M, Ejlertsen B, Colleoni M, Gelber R, Thürlimann B, Winer E, Viale G, Gusterson B, Mallon E, Giobbie-Hurder A, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. *J Clin Oncol* 2015; 33:2772-9.

Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *Lancet Oncol* 2015; 16:848-58.

Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. *Breast Cancer Res Treat* 2015; 151:373-84.

Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; 371:107-18.

Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Res Treat* 2014; 144:321-9.

Aebi S, Mamounas E, Geyer C, Price K, Coates A, Gelber R, Rastogi P, Wolmark N, Wapnir I, Murray E, Thürlimann B, Cañada J, Gelber S, Anderson S, Láng I, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *Lancet Oncol* 2014; 15:156-63.

Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. *J Clin Oncol* 2012; 30:3967-75.

Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. *J Natl Cancer Inst* 2012; 104:441-51.

Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol* 2011; 12:1101-8.

Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat* 2011; 131:295-306.

Regan M, Price K, Giobbie-Hurder A, Thürlimann B, Gelber R, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. *Breast Cancer Res* 2011; 13:209.

Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. *J Clin Oncol* 2011; 29:1117-24.

Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Sun Z, Ribí K, Aldridge J, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. *Breast Cancer Res Treat* 2010

Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Stephens A, Sun Z, Ribí K, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. *Breast* 2010; 19:388-95.

Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat* 2010; 123:303-10.

Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. *Breast Cancer Res Treat* 2009; 117:319-24.

BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *NEJM* 2009; 361:766-76.

Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Res Treat* 2009; 116:491-500.

Giobbie-Hurder A, Price K, Gelber R, International Breast Cancer Study Group, BIG 1-98 Collaborative Group. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. *Clin Trials* 2009; 6:272-87.

Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Res Treat* 2009; 113:137-44.

Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Bray S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. *J Clin Oncol* 2008; 26:5569-75.

Pestalozzi B, Goldhirsch A, Coates A, Castiglione-Gertsch M, Viale G, Murray E, Thürlimann B, Snyder R, Lindtner J, Holmberg S, Gelber R, Price K, Gusterson B, Mallon E, Zahrieh D, International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *JCO* 2008; 26:3006-14.

Crivellari D, Chirgwin J, Smith I, Rabaglio M, Gladieff L, Del Mastro L, Láng I, Colleoni M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Price K, Coates A, Sun Z, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. *JCO* 2008; 26:1972-9.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. *J Clin Oncol* 2008; 26:1404-10.

Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *J Natl Cancer Inst* 2008; 100:207-12.

Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. *The Lancet* 2008; 9:23-8.

Mouridsen H, Price K, Smith I, Colleoni M, Gelber R, Paridaens R, Forbes J, Mauriac L, Thürlimann B, Sun Z, Castiglione-Gertsch M, Rabaglio M, Coates A, Keshaviah A, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. *JCO* 2007; 25:5715-22.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol* 2007; 25:3846-52.

International Breast Cancer Study Group, Coates A, Castiglione-Gertsch M, Price K, Gelber R, Pagani O, Simoncini E, Gelber S, Colleoni M, Goldhirsch A. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. *Ann Oncol* 2007; 18:1177-84.

Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *JCO* 2007; 25:2019-26.

Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *JCO* 2007; 25:486-92.

Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. *JCO* 2007; 25:263-70.

Breast International Group (BIG) 1-98 Collaborative Group, Price K, Wardly A, Wardley A, Smith I, Rabaglio M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Coates A, Keshaviah A, Thürlimann B, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *NEJM* 2005; 353:2747-57.

Gruber G, Goldhirsch A, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Carbone A, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, International Breast Cancer Study Group. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. *JCO* 2005; 23:7089-97.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch